Synairgen Announces Upcoming Board Changes
Company Announcements

Synairgen Announces Upcoming Board Changes

Synairgen (GB:SNG) has released an update.

Synairgen plc has announced that Dr. Phillip Monk will be stepping down from the company’s Board after 18 years, effective December 31, 2024. Dr. Marcin Mankowski, who became Chief Medical Officer in 2023, will continue leading the clinical development of SNG001, Synairgen’s investigational inhaled antiviral treatment. The company also hints at upcoming Board changes as it prepares for its Annual General Meeting in early October.

For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskSynairgen Expands Share Capital with New Issuance
TipRanks UK Auto-Generated NewsdeskSynairgen Appoints New Chairman, Advances Antiviral Treatment
TipRanks UK Auto-Generated NewsdeskSynairgen Prepares for Pivotal Phase 2 Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App